Rhythm Pharmaceuticals
Boston
About Rhythm Pharmaceuticals
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $1.2B
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:RYTM
- Website: rhythmtx.com
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rhythm-pharmaceuticals-126248 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.